Loading...
Maintenance pazopanib versus placebo in non-small cell lung cancer patients non-progressive after first line chemotherapy: A double blind randomised phase III study of the lung cancer group, EORTC 08092 (EudraCT: 2010-018566-23, NCT01208064).
O'Brien, M Gaafar, R Hasan, B Menis, J Cufer, T Popat, S Woll, P Surmont, V Georgoulias, V Montes, A
O'Brien, M
Gaafar, R
Hasan, B
Menis, J
Cufer, T
Popat, S
Woll, P
Surmont, V
Georgoulias, V
Montes, A
Citations
Altmetric:
Abstract
Switch maintenance is an effective strategy in the treatment of advanced Non-Small Cell Lung Cancer (NSCLC). Pazopanib is an oral, multi-targeted tyrosine kinase inhibitor (TKI). EORTC 08092 evaluated pazopanib given as maintenance treatment following standard first line platinum-based chemotherapy in patients with advanced NSCLC.
Description
Date
2015-08
Publisher
Collections
Keywords
Type
Article
Citation
Maintenance pazopanib versus placebo in Non-Small Cell Lung Cancer patients non-progressive after first line chemotherapy: A double blind randomised phase III study of the lung cancer group, EORTC 08092 (EudraCT: 2010-018566-23, NCT01208064). 2015, 51 (12):1511-28 Eur. J. Cancer